Dextromethorphan Protect the Valproic Acid Induced Downregulation of Neutrophils in Patients with Bipolar Disorder
Ru-Band Lu1, Yun-Hsuan Chang2,3, Sheng-Yu Lee4, Tzu-Yun Wang1, Shu-Li Cheng5, Po-See Chen1, Yen-Kuang Yang1, Jau-Shyong Hong6, Shiou-Lan Chen1,7,8

1Department of Psychiatry, National Cheng Kung University Hospital, Tainan, 2Department of Psychology, Asia University, Taichung, 3Department of Medical Research, China Medical University Hospital, Taichung, 4Department of Psychiatry, Kaohsiung Veterans General Hospital, Kaohsiung, 5Department of Nursing, Mackay Medical College, Taipei, Taiwan, ROC, 6Neurobiology Laboratory, NIH/NIEHS, Research Triangle Park, NC, USA, 7Graduate Institute of Medicine & M.Sc. Program in Tropical Medicine, College of Medicine, Kaohsiung Medical University (KMU), Kaohsiung, 8Department of Medical Research, KMU Hospital, Kaohsiung, Taiwan, ROC

Objective: Valproic acid (VPA) is an anticonvulsant and commonly long term used as a mood stabilizer for patients with mood disorders. However its chronic effects on the hematological changes were noticed and need to be further evaluated. In this study, we evaluated, in Taiwanese Han Chinese patients with bipolar disorders (BD), the chronic effects of VPA or VPA plus dextromethorphan (DM) on the hematological molecules (white blood cell [WBCs], red blood cells [RBCs], hemoglobin, hematocrit, and platelets).

Methods: In a 12-week, randomized, double-blind study, we randomly assigned BD patients to one of three groups: VPA plus either placebo (VPA + P, n = 57) or DM (30 mg/day, VPA + DM30, n = 56) or 60 mg/day (VPA + DM60, n = 53). The Young Mania Rating Scale and Hamilton Depression Rating Scale were used to evaluate symptom severity, and the hematological molecules were checked.

Results: Paired t test showed that the WBC, neutrophils, platelets and RBCs were significantly lowered after 12 weeks of VPA + P or VPA + DM30 treatment. VPA + DM60 represented the protective effects in the WBCs, neutrophils, and RBCs but not in the platelets. We further calculated the changes of each hematological molecules after 12 weeks treatment. We found that combination use of DM60 significantly improved the decline in neutrophils induced by the long-term VPA treatment.

Conclusion: Hematological molecule levels were lower after long-term treatment with VPA. VPA + DM60, which yielded the protective effect in hematological change, especially in the neutrophil counts. Thus, DM might be adjunct therapy for maintaining hematological molecules in VPA treatment.

KEY WORDS: Bipolar disorder; Dextromethorphan; Neutrophils; Blood platelets; Erythrocytes; Valproic acid.

INTRODUCTION
Valproic acid (VPA) is conventionally used to treat epilepsy. VPA is also extensively used as a first-line mood stabilizer in patients with bipolar disorder (BD) for months and years. Thus, the chronic side effects of VPA needed to be closely observed. In addition, accumulating evidence suggests that VPA treatment significantly may reduce the levels of hemoglobin [1], platelets [2,3] and neutrophils [4]. In young new BD patients, chronic VPA treatment caused thrombocytopenia [2]. In female but not the male patients with BD, a significant negative correlation between serum VPA level and platelet count was found [3]. Moreover, a 13-year-old Caucasian boy were demonstrated having mild anemia 12 months after the introduction of VPA therapy [1]. A 56-year-old white woman with tonic-clonic seizure and treated with VPA, developed severe neutropenia after 2 days of VPA therapy [4]. Thus, keeping the blood concentration of VPA at a safe therapeutic level (ca. 80 μg/ml) and closely monitoring
the hematological toxicity during VPA treatment are noticed [3]. Furthermore, in addition to controlling blood levels of VPA, adjunct therapy combined with long-term VPA treatment to prevent hematological deterioration might be helpful.

In addition, because prior studies on hematological changes in patients treated with VPA were case reports and prospective observation studies rather than intervention studies, they did not control for confounding factors or analyze the time effects of VPA on the hematological changes. Thus, time effects and adjunct treatments require investigation.

Moreover, our previous study, in two medical centers National Cheng Kung University (NCKU) Hospital and National Defense Medical Center, showed that combination of dextromethorphan (DM) with VPA provided the therapeutic benefit in the plasma brain-derived neurotrophic factor (BDNF) levels of BD [5]. DM is a dextro-rotatory opioid derivative that does not act on opioid receptors, it has been used as an antitussive drug with few side effects for more than 60 years. Previously study showed that femtomolar concentrations of dextromethorphan protected mesencephalic dopaminergic neurons in neuron-glia culture [6]. Thus, combination of DM not only provided benefit in plasma BDNF expression but also may has the neuronal protective effects [5] of BD. Moreover, DM also represented a significant cardiovascular protective effects. Study showed that low-dose of DM could reduce the blood pressure and enhances vascular protection through NADPH oxidase inhibition in rat [7]. Thus, we hypothesized that DM might has the hematological protective effects and that VPA plus DM would be more beneficial in the changes of hematology than would VPA-only for BD patients.

In the present study, we evaluated the chronic effects of long-term VPA-only therapy on hematological changes in a 12-week follow-up study. In NCKU Hospital, we collected and analyzed the related parameters in patients with BD. In addition, the protective effects of combination of DM (30 to 60 mg/day) with VPA in the changing of hematology were also evaluated.

**METHODS**

**Patient Selection**

We recruited the Taiwanese Han Chinese BD patients from the Department of Psychiatry at NCKU Hospital, Tainan. The NCKU Institutional Review Boards (IRB) for the Protection of Human Subjects approved the study protocol (IRB no. HR-95-110). After the study had been completely described to the participants, they all signed written informed consent forms.

The inclusion criteria were: (A) being a psychiatric in-patient or outpatient who sought psychiatric care or had been referred for psychiatric evaluation because suspected of having a mood disorder; (B) a diagnosis of BD-I or BD-II based on the Diagnostic and Statistical Manual of Mental Disorders 4th edition (DSM-IV) criteria and confirmed by the Chinese version of the modified Schedule for Affective Disorders and Schizophrenia-Lifetime (SADS-L); (C) being between 18 and 65 years old; (D) a Hamilton Depression Rating Scale (HDRS) score of at least 18 or a Young Mania Rating Scale (YMRS) score of at least 14 at the screening stage; (E) able to communicate in Mandarin Chinese or Taiwanese; (F) a signed informed consent form; and (G) attendance and compliance with the terms of the study ensured by the patient or the patient’s caregiver.

The modified version of SADS-L, a semi-structured interview with good inter-rater reliability [8,9], was used as the gold standard. The diagnoses of a mood disorder were made based on DSM-IV criteria, except for BD-II, for which the 4-day duration criterion for hypomania was replaced with a 2-day criterion because the 4-day minimum might not be evidence-based [10]. The 2-day criterion has been supported by several studies [11].

Exclusion criteria were: (A) being pregnant or breastfeeding an infant; (B) having taken DM within 1 week before the first dose of the double-blind study medication; (C) a major mental illness other than BD, e.g., alcoholism or an illegal substance use disorder; (D) having a poorly controlled clinically significant medical condition, e.g., cardiac, hepatic, or renal disease; (E) having undergone electroconvulsive therapy within 4 weeks before the first dose of the double-blind study medication; (F) total aspartate aminotransferase, alanine aminotransferase, blood urea nitrogen, or creatinine levels three times higher than normal.

**Study Design**

Patients first underwent one week of daily open-label VPA-only treatment (500 − 1,000 mg daily [50 − 100 µg/ml
in plasma). They were then randomly assigned to VPA plus placebo (VPA + P), VPA + 30 mg/day of extended-release DM (VPA + DM30), and VPA + 60 mg/day of extended-release DM (VPA + DM60) treatment groups. A concomitant benzodiazepine (preferably lorazepam [1 – 4 mg]) was used for nighttime sedation, agitation, or insomnia during the study. Risperidone (1 – 6 mg/day) and fluoxetine (20 mg/day) were permitted during symptomatic mood episodes, and an anticholinergic drug was used for extrapyramidal syndrome.

**Measurement of Mood State**

The severity of current symptoms was assessed using the YMRS and HDRS.

**Blood Sample Assessment**

Ten milliliters of whole blood was drawn from the antecubital vein of each patient during the initial visit and again at 12 weeks. WBCs, neutrophils, eosinophils, basophils, monocytes, lymphocytes, RBCs, and platelets were counted, and hemoglobin and hematocrit levels measured.

**Statistical Analysis**

Data are means ± standard error of the mean. Paired t tests were used to evaluate hematological molecular changes before (visit) and after 12 weeks of treatment. The changes of each hematological molecules after 12 weeks treatment between groups were analyzed by One-Way ANOVA with Tucky post-hoc test. Significance was set at p < 0.05. Prism 5 (GraphPad Software, La Jolla, CA, USA) and SPSS 22 (IBM Co., Armonk, NY, USA) were used to analyze the data.

**RESULTS**

Initially, 255 BD patients from NCKU hospital were enrolled and randomly assigned to one of the three different treatment groups, but 89 patients (34.9%) dropped out during the 12-week trial (dropout rate: VPA + P, n = 29 [33.7%]; VPA + DM30, n = 29 [34.1%]; VPA + DM60, n = 31 [36.9%]) (Fig. 1). The reasons for dropping out were:

1. attempted suicide or poor tolerance of side effects (VPA + P, n = 4 VPA + DM30, n = 1; VPA + DM60, n = 1);
2. insufficient therapeutic response (VPA + DM60, n = 2);
3. lost to follow-up for unknown reason (VPA + P, n = 11; VPA + DM30, n = 11; VPA + DM60, n = 13);
4. refused treatment (VPA + P, n = 7; VPA + DM30, n = 3; VPA + DM60, n = 1);
5. violation of protocol and poor drug compliance (VPA + P, n = 1; VPA + DM60, n = 2); and
6. administrative reasons (VPA + P, n = 5; VPA + DM30, n = 9; VPA + DM60, n = 12).

Finally, 166 BD patients (65.1%) completed the 12-week double-blind study (VPA + P, n = 57; VPA + DM30, n = 56; VPA + DM60, n = 53) (Fig. 1). There were no differences in demographic data between these three groups (Table 1). Neither sex nor BD-type differences (BD-I vs. BD-II) were significantly different between groups. Nor were the mean age, height, body weight, plasma levels of VPA at week 2 and week 12, or HDRS and YMRS scores significantly different at visit (Table 1). We also checked the blood DM and its metabolites dextrorphan (DX) concentration. We found that the slow-release DM30 and DM60 yielded 5-800 ng/ml of DM (4.8 – 15.5 ng/ml of mean concentration) and DX (10.3 – 24.1 ng/ml of mean concentration) in the blood (Table 1).

**VPA + DM60 Improved the Long Term VPA Induced Downregulation of WBCs and Neutrophils**

A paired t test showed that after 12 weeks of VPA + P, or VPA + DM30 treatment, WBCs and neutrophils counts were significantly downregulated, but not in the group given VPA + DM60 (Table 2). To further verify the effects of DM, We calculated the changes of each hematological molecules after 12 weeks treatment. We found that com-
Table 1. Demographic data

| Variable               | VPA + P (n = 57) | VPA + DM30 (n = 56) | VPA + DM60 (n = 53) | χ², F | p value |
|------------------------|------------------|---------------------|---------------------|-------|---------|
| Sex (F/M)              | 29/28            | 30/26               | 23/30               | χ² = 1.20 | 0.55*   |
| BD-I/BD-II             | 21/34            | 25/30               | 26/24               | F = 0.15 | 0.87#   |
| Age (yr)               | 30.6 ± 1.4       | 30.0 ± 1.5          | 29.5 ± 1.3          | F = 0.15 | 0.87#   |
| Height (cm)            | 165.6 ± 1.1      | 164.2 ± 1.3         | 167.6 ± 1.2         | F = 1.92 | 0.15#   |
| Body weight (kg)       | 61.5 ± 1.6       | 65.3 ± 2.2          | 65.9 ± 2.5          | F = 1.27 | 0.28#   |
| Plasma VPA (µg/ml, W2) | 58.8 ± 4.3       | 69.5 ± 4.7          | 72.9 ± 3.9          | F = 2.81 | 0.06#   |
| Plasma VPA (µg/ml, W12)| 52.8 ± 6.1       | 54.7 ± 5.6          | 57.0 ± 5.6          | F = 0.13 | 0.88#   |
| Plasma DM (ng/ml, W12) | 0.0 ± 0.0        | 4.8 ± 1.5           | 15.5 ± 3.5***       | F = 13.24 | < 0.0001b |
| Plasma DX (ng/ml, W12) | 0.0 ± 0.0        | 10.3 ± 1.3          | 24.1 ± 4.0***       | F = 25.13 | < 0.0001b |
| HDRS at visit          | 16.9 ± 0.8       | 16.5 ± 0.8          | 15.4 ± 0.9          | F = 0.89 | 0.41b   |
| YMRS at visit          | 10.6 ± 0.7       | 10.9 ± 0.7          | 12.2 ± 0.7          | F = 1.38 | 0.26b   |

Values are presented as mean ± standard error of the mean.
VPA, valproic acid; W, week; DM, dextromethorphan; DX, dextrorphan; F, female; M, male; YMRS, Young Mania Rating Scale; HDRS, Hamilton Depression Rating Scale.

Table 2. White blood cells and related molecules before and after 12 weeks of treatment in each group

| Blood cell counts in per cmm | VPA + P (n = 57) | VPA + DM30 (n = 56) | VPA + DM60 (n = 53) |
|------------------------------|------------------|---------------------|---------------------|
|                              | Visit Week 12    | p value             | Visit Week 12       | p value |
| WBCs                         | 6,435.7 ± 238    | 5,887.1 ± 193*      | 0.018               | 6,705.5 ± 245 | 6,221.6 ± 190* | 0.035 |
| Neutrophils                  | 3,864.2 ± 211    | 3,261.1 ± 173**     | 0.004               | 4,131.0 ± 193 | 3,543.9 ± 144** | 0.006 |
| Eosinophils                  | 163.1 ± 20.1     | 166.6 ± 17.4        | 0.77                | 156.4 ± 16.6 | 166.4 ± 30.0 | 0.72 |
| Basophils                    | 36.0 ± 2.8       | 34.8 ± 2.3          | 0.51                | 32.4 ± 1.8 | 28.6 ± 1.8 | 0.05 |
| Monocytes                    | 483.5 ± 27.1     | 485.0 ± 20.2        | 0.96                | 463.2 ± 22.5 | 469.7 ± 17.3 | 0.77 |
| Lymphocytes                  | 1,897.3 ± 58.4   | 1,939.5 ± 58.8      | 0.45                | 1,883.4 ± 89.3 | 1,976.5 ± 73.3 | 0.22 |

Values are presented as mean ± standard error of the mean.
WBCs, white blood cells; VPA, valproic acid; DM, dextromethorphan.

DISCUSSION

This pilot study investigated the effects of DM on hematological changes induced by chronic VPA treatment. WBCs and their differential counts (neutrophils, eosinophils, basophils, monocytes, and lymphocytes), RBCs, hemoglobin, hematocrit, and platelet counts were measured before and after VPA treatment. We found that 12 weeks of VPA-alone treatment had induced significantly lower levels of WBCs, neutrophils, RBCs, hemoglobin, hematocrit, and platelet counts in adult Taiwanese Han Chinese BD patients. In contrast, VPA + DM60 treatment protected against VPA-induced hematological changes. Of notice, BD patients treated with VPA + DM60 significantly im-
Dextromethorphan Protect the Valproic Acid Induced Downregulation of Neutrophils

Fig. 2. The changes of hematological molecules in patients with bipolar disorder (BD) after 12 weeks treatment with VPA + Placebo (n = 57), VPA + DM30 (n = 56) and VPA + DM60 (n = 53). The changes of (A) white blood cell (WBC) counts, (B) neutrophils counts, (C) red blood cell (RBC) counts and (D) platelet counts were calculated and analyzed between groups. All data are mean ± standard error of the mean. All measurement are cell counts in one cubic millimeters (cmm); *p < 0.05, vs. VPA + Placebo group (One-Way ANOVA with Tucky post-hoc test).
DM, dextromethorphan. VPA, valproic acid.

Table 3. Platelets, red blood cells and related molecules before and after 12 weeks of treatment in each group

| Blood cell counts in per cmm | VPA + P (n = 57) | VPA + DM30 (n = 56) | VPA + DM60 (n = 53) |
|-----------------------------|-----------------|---------------------|---------------------|
| Visit                       | Visitor         | Week 12             | p value             | Visitor         | Week 12             | p value             | Visitor         | Week 12             | p value             |
| Platelets (x10^3/cmm)       | 251.5 ± 8.4     | 225.7 ± 7.4***      | < 0.0001            | 249.9 ± 7.1        | 225.1 ± 6.4**     | < 0.0001            | 261.2 ± 9.0      | 231.0 ± 7.2**      | 0.001               |
| RBCs (x10^6/cmm)            | 4.73 ± 0.1      | 4.56 ± 0.1***       | < 0.0001            | 4.58 ± 0.1         | 4.45 ± 0.1**      | 0.007               | 4.61 ± 0.1       | 4.57 ± 0.1         | 0.51                |
| Hemoglobin (gm/ml)          | 14.3 ± 0.2      | 14.0 ± 0.2**        | 0.010               | 14.0 ± 0.2         | 13.8 ± 0.2*       | 0.04                | 13.9 ± 0.2       | 13.9 ± 0.2         | 0.94                |
| Hematocrit (%)              | 42.2 ± 0.7      | 41.0 ± 0.5**        | 0.005               | 41.1 ± 0.5         | 40.3 ± 0.5*       | 0.012               | 40.7 ± 0.7       | 41.0 ± 0.5         | 0.50                |

Values are presented as mean ± standard error of the mean. RBCs, red blood cell; VPA, valproic acid; DM, dextromethorphan. Most of measurement are cell counts in one cubic millimeters (cmm) or protein weight (gm) in one milliliter (ml). *p < 0.05, **p < 0.01, ***p < 0.001 vs. visit within same group (paired t test).

proved the long term VPA induced downregulation of neutrophil counts.

The common therapeutic range recommended for VPA is 50 – 125 μg/ml [12]. In clinic, monitoring the therapeutic blood concentration of VPA is recommend to prevent the toxic effects of VPA. However, the toxic and therapeutic effects of VPA are considered poorly correlated with its concentrations in children’s blood [13]. The therapeutic s concentrations of VPA also vary in different adult patients [14]. Thus, the pharmacokinetic, ther-
oxidation in the mitochondria, and about 10% expression in vitro [23] which support the possible drug inhibits CYP2C9, CYP3A4 [22] or induces CYP3A4 gene CYP2C19, CYP2D6, and CYP3A [20,21]; and that VPA transformation of DM, including the enzymes CYP2C9, CYP2C19, CYP2D6, and CYP3A [20,21]; and that VPA affects by the same enzymes: CYP2C9 and CYP3A4; that multiple human cytochromes contribute to the bio-chemistry changes in human subjects requires additional study. To verify the effects and mechanisms of DM on the hematol-ogy, in vitro or in vivo studies to verify the drug effects of VPA in hematol-ogy, especially in the neutrophils counts.

This is the first finding of DM in hematological changes. DM was reported acting as a noncompetitive Nmethyl-D-aspartate (NMDA) receptor antagonist [27,28] and sigma-1 receptor agonist [29,30]. DM and its metabolite DX binding at sigma-1 receptors with high affinities at nano-molar (nM) range [31] and with lower affinities on NMDA receptors at micromolar (µM) range [27,28,30] in vitro and in rodent brain. Previous studies had showed that in human plasma [34], leukocytes [35] and lymphocytes [36]. In the current study, the levels of DM and DX in our patients taking with slow-release DM60 are in ng/ml range (Table 1). Thus, in our participants, DM may be insufficient to block NMDA receptors. DM may affect the blood cell through the sigma-1 receptor pathway. In addition, we previously showed that femtomolar concentrations of DM protected mesencephalic dopaminergic neurons in a neuron-glia culture [6]. However, the mechanism that DM uses to protect against hematological changes in human subjects requires additional study. To verify the effects and mechanisms of DM on the hematol-ogy, in vitro or in vivo experiment with pharmacological approach is needed in the future.

Our study has some limitations. First, the longer follow-up duration was needed in the further study. Although we did the 12 weeks observation, however, the longer ob-ervation period and more subjects enrolled will provide the more evident results. Second, medication permitted in the study might affect the hematology and obscure the changes in blood cells. Due to medical ethics, appropriate medications must be given to the subject’s symptoms. We tried our best to limit concomitant treatment medication to only three drug such as lorazepam, risperidone and anticholinergic. Other medications, such as traditional herbal medicines, are excluded as much as possible during initial screening and treatment evaluation. However, we could not exclude the possible interaction induced by these adjunctive drugs with treatment group. Therefore, in vitro or in vivo studies to verify the drug effects of VPA and VPA + DM are needed.

Taken together, our data support our hypothesis that combination of such low-dose of DM with VPA is safe [5,37] and protect VPA-induced reductions of blood cell
counts. We suggested that using low dose of DM with VPA might as an ideal adjunct therapy to protect the peripheral blood cell counts in BD.

Chronic VPA-only treatment significantly lowered blood-cell counts in Taiwanese Han Chinese BD patients. Regular monitoring of blood cell counts is important during VPA treatment. VPA + DM60 treatment did not affect the pharmacokinetics of VPA, but it did significantly benefit the therapeutic effects and protect against the reduction of blood cell counts caused by VPA. With the therapeutic advantages both in plasma BDNF expression [5] and hematology, DM may be considered as an adjunct treatment with the VPA in BD treatment.

■ Acknowledgments

This work was supported by Taiwan Ministry of Science and Technology (MOST) grants MOST 105-2314-B-006-007-MY2 (to RBL) and MOST 105-2628-B-037-003-MY3 (to SLC). This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

■ Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

■ Author Contributions

Designed the study and wrote the protocol: Ru -Band Lu, Jau-Shyong Hong, Shiou-Lan Chen. Managed the literature searches and analyses: Shiou-Lan Chen, Yun-Hsuan Chang. Collected and followed up the clinic subjects: Tzu-Yun Wang, Sheng-Yu Lee, Shiou-Lan Chen, Po-See Chen, Yen-Kuang Yang. Wrote the first draft of the manuscript: Shiou-Lan Chen. All authors contributed to and have approved the final manuscript.

■ ORCID

Ru -Band Lu https://orcid.org/0000-0001-6411-3547
Yun-Hsuan Chang https://orcid.org/0000-0001-8662-2457
Sheng-Yu Lee https://orcid.org/0000-0001-7796-9643
Tzu-Yun Wang https://orcid.org/0000-0002-0566-9967
Shu-Li Cheng https://orcid.org/0000-0002-1523-8519
Po-See Chen https://orcid.org/0000-0003-4963-578X
Yen-Kuang Yang https://orcid.org/0000-0001-9355-9636
Jau-Shyong Hong https://orcid.org/0000-0002-3056-8401
Shiou-Lan Chen https://orcid.org/0000-0003-3995-0276

REFERENCES

1. Kaczorowska-Hac B, Matheisel A, Maciejka-Kapuscinska L, Wisniewski J, Alksa A, Adamkiewicz-Drozynska E, et al. Anemia secondary to valproic acid therapy in a 13-year-old boy: a case report. J Med Case Rep 2012;6:239.
2. De Berardis D, Carpanella D, Materia V, Gambi F, La Rovere R, Sepede G, et al. Thrombocytopenia during valproic acid treatment in young patients with new-onset bipolar disorder. J Clin Psychopharmacol 2003;23:451-458.
3. Vasudev K, Keown P, Gibb I, McAllister-Williams RH. Hematological effects of valproate in psychiatric patients: what are the risk factors? J Clin Psychopharmacol 2010;30:282-285.
4. Vesta KS, Medina PJ. Valproic acid-induced neutropenia. Ann Pharmacother 2003;37:819-821.
5. Chen SL, Lee SY, Chang YH, Chen PS, Lee IH, Wang TY, et al. Therapeutic effects of add-on low-dose dextromethorphan plus valproic acid in bipolar disorder. Eur Neuropsychopharmacol 2014;24:1753-1759.
6. Li G, Cui G, Tseng NS, Wei SJ, Wang T, Block ML, et al. Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage. FASEB J 2005;19:489-496.
7. Wu TC, Chao CY, Lin SJ, Chen JW. Low-dose dextromethorphan, a NADPH oxidase inhibitor, reduces blood pressure and enhances vascular protection in experimental hypertension. PLoS One 2012;7:e46067.
8. Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978;35:837-844.
9. Huang SY, Lin WW, Ko HC, Lee JF, Wang TJ, Chou YH, et al. Possible interaction of alcohol dehydrogenase and aldehyde dehydrogenase genes with the dopamine D2 receptor gene in anxiety-depressive alcohol dependence. Alcohol Clin Exp Res 2004;28:374-384.
10. Dunner DL. Diagnostic revisions for DSM-IV. In: Goodnick PJ, editor. Mania: clinical and research perspectives. Washington D.C.:American Psychiatric Press;1998. p.3-10.
11. Benazzi F, Akiskal H. The duration of hypomania in bipolar-II disorder in private practice: methodology and validation. J Affect Disord 2006;96:189-196.
12. Jackson J, McCollum B, Ognibene J, Diaz FJ, de Leon J. Three patients needing high doses of valproic Acid to get therapeutic concentrations. Case Rep Psychiatry 2015;2015:205920862.
13. Serrano BB, García Sánchez MJ, Otero MJ, Buelga DS, Serrano J, Dominguez-Gil A. Valproate population pharmacokinetics in children. J Clin Pharm Ther 1999;24:73-80.
14. Blanco-Serrano B, Otero MJ, Santos-Buelga D, García-Sánchez MJ, Serrano J, Dominguez-Gil A. Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data. Biopharm Drug Dispos 1999;20:233-240.
15. Cloyd JC, Dutta S, Cao G, Walsh JK, Collins SD, Granneman GR. Valproate unbound fraction and distribution volume fol-
lowing rapid infusions in patients with epilepsy. Epilepsy Res 2003;53:19-27.

16. Leppik IE, Birnbaum AK. Epilepsy in the elderly. Ann N Y Acad Sci 2010;1184:208-224.

17. Yu HY, Shen YZ. Glucuronidation metabolic kinetics of valproic acid in guinea pigs: nonlinear at clinical concentration levels. Pharm Res 1996;13:1243-1246.

18. Argikar VA, Remmel RP. Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos 2009;37:229-236.

19. Tan L, Yu JT, Sun YP, Ou JR, Song JH, Yu Y. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin Neurol Neurosurg 2010;112:320-323.

20. von Moitke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Schmidt J, et al. Multiple human cytochromes contribute to biotransformation of dextromethorphan in vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol 1998;50:997-1004.

21. Yu A, Haining RL. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isozymes in vitro: can dextromethorphan be used as a dual probe for both CYP2D6 and CYP3A activities? Drug Metab Dispos 2001;29:1514-1520.

22. Wen X, Wang JS, Kivistö KT, Neuvonen PJ, Backman JT. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isozymes: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol 2001;52:547-553.

23. Cerverny L, Svecova L, Anzenbacherova E, Vrzal R, Staud F, Dvorak Z, et al. Valproic acid induces CYP3A4 and MDRI gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos 2007;35:1032-1041.

24. Shah RR, Konisky A, Shinde M, Blythe SA, Fass DM, Haggarty SJ, et al. Regulation of primitive hematopoiesis by class I histone deacetylases. Dev Dyn 2013;242:108-121.

25. Loisseau P, Martinez-Lage JM. Clinical irrelevance of the hematologic side effects of sodium valproate (Depakine). Rev Med Univ Navarra 1981;25:14-16. Spanish.

26. Li R, Liang L, Wu X, Ma X, Su M. Valproate-acid (VPA)-induced dysmetabolic function in clinical and animal studies. Clin Chim Acta 2017;468:1-4.

27. Netzer R, Flimlin P, Trube G. Dextromethorphan blocks N-methyl-D-aspartate-induced currents and voltage-operated inward currents in cultured cortical neurons. Eur J Pharmacol 1993;238:209-216.

28. Church J, Sawyer D, McLamon JG. Interactions of dextromethorphan with the N-methyl-D-aspartate receptor-channel complex: single channel recordings. Brain Res 1994;666:189-194.

29. Kamei H, Kameyama T, Nabeshima T. (+)-SKF-10,047 and dextromethorphan ameliorate conditioned fear stress through the activation of phenylethanolamine N-methyltransferase 1 sites. Eur J Pharmacol 1999;369:21-28.

30. Taylor CP, Trayanos SF, Silliet J, Pope LE, Matsumoto RR. Pharmacology of dextromethorphan: relevance to dextromethorphan-quinidine (Nuedexta®) clinical use. Pharmacol Ther 2016;164:170-182.

31. Shin EJ, Nah SY, Chae JS, Bing G, Shin SW, Yen TP, et al. Dextromethorphan attenuates trimethyltin-induced neurotoxicity via sigma receptor activation in rats. Neurochem Int 2007;50:791-799.

32. Makhro A, Kaestner L, Bogdanova A. NMDA receptor activity in circulating red blood cells: methods of detection. Methods Mol Biol 2017;1677:263-282.

33. Li JT, Wang WQ, Wang L, Liu NN, Zhao YL, Zhu XS, et al. Subanesthetic isoflurane relieves zymosan-induced neutrophil inflammatory response by targeting NMDA glutamate receptor and Toll-like receptor 2 signaling. Oncotarget 2016;7:31772-31789.

34. Shimizu H, Takehashi M, Tani M, Tanaka H, Yamagata B, Kurosawa K, et al. Sigma-1 receptor concentration in plasma of patients with late-life depression: a preliminary study. Neuropsychiatr Dis Treat 2013;9:1867-1872.

35. Wolfe SA Jr, Kulsakdinun C, Battaglia G, Jaffe JH, De Souza EB. Initial identification and characterization of sigma receptors on human peripheral blood leukocytes. J Pharmacol Exp Ther 1988;247:1114-1119.

36. Paul R, Lavastre S, Floutard D, Floutard R, Canat X, Casellas P, et al. Allosteric modulation of peripheral sigma binding sites by a new selective ligand: SR 31747. J Neuroimmunol 1994;52:183-192.

37. Lee SY, Chen SL, Wang TY, Chang YH, Chen PS, Huang SY, et al. The COMT Val158Met polymorphism is associated with response to add-on dextromethorphan treatment in bipolar disorder. J Clin Psychopharmacol 2017;37:94-98.